Ulrich Ronellenfitsch

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 713 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +12

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · JAMA Oncology · 2017 · 458 citations · Full text

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

James Glasbey, Adesoji Ademuyiwa, Adewale Adisa et al. · The Lancet Oncology · 2021 · 280 citations · Full text

Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour

Peter Hohenberger, Ulrich Ronellenfitsch, Oluwole Solomon Oladeji et al. · British journal of surgery · 2010 · 209 citations · Full text

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

Chiara Mussi, Ulrich Ronellenfitsch, Jens Jakob et al. · Annals of Oncology · 2009 · 152 citations · Full text

Surgical Oncology, Medicine, Surgery +4